A Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653H in Japanese Participants With Hypercholesterolemia (MK-0653H-833)

Hypercholesterolemia Clinical Trial

Official title:

A Phase III, Open-label, Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653H in Japanese Patients With Hypercholesterolemia Who Have Inadequate LDL-C Control on Ezetimibe or Rosuvastatin Monotherapy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02748057
• Other study ID #: 0653H-833
• Secondary ID: 163314MK-0653H-8
• Status: Completed
• Phase: Phase 3
• Start date: May 18, 2016
• Est. completion date: December 11, 2017

Study information

• Verified date: February 2022
• Source: Organon and Co
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study will assess the safety and tolerability of Ezetimibe 10 mg+ Rosuvastatin 2.5 mg and Ezetimibe 10 mg+ Rosuvastatin 5.0 mg for up to 52 weeks in Japanese participants with hypercholesterolemia uncontrolled with monotherapy of Ezetimibe 10 mg or Rosuvastatin up to 5 mg.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 135
• Est. completion date: December 11, 2017
• Est. primary completion date: December 11, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years to 80 Years

Eligibility

Inclusion Criteria:

• Japanese

• Outpatient with hypercholesterolemia

• Female participant who is of reproductive potential has to agree to remain abstinent or use (or partner use) two acceptable methods of birth control from date of signed informed consent to the 14 days after the last dose of study drug

• Will maintain a stable diet that is consistent with the Japan Atherosclerosis Society Guideline 2012 (JAS 2012) for prevention of atherosclerotic cardiovascular diseases for the duration of the study

Exclusion Criteria:

• Uncontrolled hypertension (treated or untreated)

• Uncontrolled type 1 or type 2 diabetes mellitus

• Homozygous Familial Hypercholesterolemia or has undergone low-density lipoprotein (LDL) apheresis

• Uncontrolled endocrine or metabolic disease known to influence serum lipids or lipoproteins

• Has had a gastrointestinal tract bypass, or other significant intestinal malabsorption

• History of cancer within the past 5 years (except for successfully treated dermatological basal cell or squamous cell carcinoma or in situ cervical cancer)

• Human Immunodeficiency Virus (HIV) positive

• History of drug/alcohol abuse within the past 5 years or psychiatric illness not adequately controlled and stable on pharmacotherapy

• Consumes more than 25 g of alcohol per day

• Currently following an excessive weight reduction diet

• Currently engages in a vigorous exercise regimen (e.g.; marathon training, body building training etc.) or intends to start training during the study

• Hypersensitivity or intolerance to Ezetimibe or Rosuvastatin

• Myopathy or rhabdomyolysis with Ezetimibe or any statin

• Pregnant or lactating

• Taking any other investigational drugs and/or has taken any investigational drugs within 30 days

Related Conditions & MeSH terms

• Familial Hypercholesterolemia
• Hypercholesterolemia
• Hyperlipoproteinemia Type II

Intervention

Drug:
• Ezetimibe

• Rosuvastatin

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Organon and Co

References & Publications (1)

Teramoto T, Yokote K, Nishida C, Oshima N, Takase T. A Phase III Open-label clinical trial to assess the long-term safety of ezetimibe and rosuvastatin combination therapy in Japanese patients with hypercholesterolemia. J Clin Therapeut Med. 2018;34(11):7

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Participants Who Experience at Least 1 Adverse Event (AE)	An AE was any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of a medicinal product, regardless of whether or not it was considered related to the medicinal product. The percentage of participants who reported at least 1 AE was summarized.	Up to 2 weeks post last dose of study drug (up to 54 weeks)
Primary	Percentage of Participants Who Had Study Drug Discontinued Due to an AE	An AE was any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of a medicinal product, regardless of whether or not it was considered related to the medicinal product. The percentage of participants who had study drug discontinued due to an AE was summarized.	up to 52 weeks
Secondary	Percentage Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C)	Blood was collected at baseline (predose) and after 52 weeks of treatment to determine LDL-C levels. LDL-C was calculated using the Friedewald equation. If triglycerides (TG) exceeded 400 mg/dL (4.6 mmol/L), LDL-C was determined by beta quantification ultracentrifugation. The percentage change from baseline at Week 52 was summarized.	Baseline (predose) and Week 52